Table I.
Summary of LCL161 activity In vitro
| Cell Line | Histology | Relative IC50 (μM) | Ymin % (Observed) |
|---|---|---|---|
| RD | Rhabdomyosarcoma | < 10 | 78.1 |
| Rh41 | Rhabdomyosarcoma | < 10 | 58.9 |
| Rh18 | Rhabdomyosarcoma | < 10 | 61.1 |
| Rh30 | Rhabdomyosarcoma | < 10 | 71.6 |
| BT-12 | Rhabdoid | < 10 | 86.3 |
| CHLA-266 | Rhabdoid | < 10 | 68.7 |
| TC-71 | Ewing sarcoma | < 10 | 84.0 |
| CHLA-9 | Ewing sarcoma | < 10 | 84.4 |
| CHLA-10 | Ewing sarcoma | < 10 | 64.7 |
| CHLA-258 | Ewing sarcoma | < 10 | 53.3 |
| GBM2 | Glioblastoma | < 10 | 72.4 |
| NB-1643 | Neuroblastoma | < 10 | 94.1 |
| NB-EBc1 | Neuroblastoma | < 10 | 80.5 |
| CHLA-90 | Neuroblastoma | < 10 | 73.6 |
| CHLA-136 | Neuroblastoma | < 10 | 97.0 |
| NALM-6 | ALL | < 10 | 50.6 |
| COG-LL-317 | ALL | 9.3 | 46.8 |
| RS4;11 | ALL | < 10 | 63.9 |
| MOLT-4 | ALL | < 10 | 75.3 |
| CCRF-CEM | ALL | 0.25 | 12.5 |
| Kasumi-1 | AML | < 10 | 53.4 |
| Karpas-299 | ALCL | 1.60 | 4.9 |
| Ramos-RA1 | NHL | < 10 | 52.2 |
| Median | < 10 | 68.7 | |
| Minimum | 0.25 | 4.9 | |
| Maximum | < 10 | 97.0 |
ALCL, anaplastic large cell lymphoma.